Amgen Inc. decided to discontinue clinical development ofplatelet derived growth factor (PDGF) for treating bedsores inthe spring of 1993 because the company did not see sufficientefficacy of the wound healing agent to make it a cost-effectiveproduct. Amgen's product did show biological activity in thehuman trials, however.

(c) 1997 American Health Consultants. All rights reserved.